Imaging and therapy of gastrointestinal cancers with radiolabeled antibodies

Area of Science:

• Oncology
• Immunology
• Radiochemistry

Background:

• Radiolabeled antibodies represent a significant advancement in cancer diagnostics and therapeutics.
• Their application is particularly notable for gastrointestinal tumors, with ongoing research addressing current challenges.

Purpose of the Study:

• To review the current status, challenges, and future prospects of radiolabeled antibodies in cancer imaging and therapy.
• To highlight advancements in utilizing these biological reagents for improved tumor detection and treatment.

Main Methods:

• Utilizing murine monoclonal antibodies targeting cancer-associated antigens for tumor visualization.
• Employing antibody fragments and direct labeling techniques with Technetium-99m (99mTc) for enhanced imaging.
• Investigating the attachment of therapeutic radionuclides (e.g., Yttrium-90, Rhenium-186/188) for targeted cancer therapy.

Main Results:

• Murine monoclonal antibodies demonstrate safety and efficacy in detecting a high percentage of tumor sites, including those undetectable by conventional radiological methods.
• Small tumors (as little as 0.5 cm) can be identified, even in challenging anatomical locations for CT interpretation.
• Advancements in antibody fragment use and 99mTc labeling have significantly improved cancer imaging capabilities.

Conclusions:

• Radiolabeled antibodies are safe and effective tools for cancer imaging, offering superior detection rates for certain tumors.
• Therapeutic applications face challenges in delivering adequate radiation doses, but advancements like antibody humanization and improved radionuclide attachment show promise.
• Future directions involve refining these techniques for more effective cancer treatment strategies.